Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Intuitive Surgical, Inc.    ISRG

Delayed Quote. Delayed  - 08/31 04:06:52 pm
685.9 USD   -0.24%
08/19 INTUITIVE SURGI : Reports New Employee Option Grants for August 2016
08/17 Intuitive Surgical Reports New Employee Option Grants for August ..
08/17 INTUITIVE SURGI : New Study Shows Robotic-Assisted Surgery Benefits ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Intuitive Surgical, Inc. : Hagens Berman Notifies Investors of June 25, 2013, Lead Plaintiff Deadline in Intuitive Surgical, Inc. Securities Class Action

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/29/2013 | 03:30pm CEST

Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, today notified investors of a pending June 25, 2013, deadline to file for lead plaintiff in a securities class-action lawsuit brought again Intuitive Surgical, Inc. (NASDAQ: ISRG) ("ISRG" or "the company"). The firm encourages investors with more than $500,000 in losses to contact Hagens Berman Partner Reed Kathrein to discuss moving for lead plaintiff by emailing ISRG@hbsslaw.com or calling (510) 725-3000.

Investors who purchased ISRG common stock between Oct. 19, 2011, and April 18, 2013, (the "class period") and have more than $500,000 in losses can also reach an attorney by visiting http://www.hb-securities.com/investigations/ISRG.

The lawsuit, filed in U.S. District Court for the Northern District of California on April 26, 2013, alleges that ISRG issued a series of false or misleading statements to investors during the class period. The suit alleges that ISRG failed to fully disclose to investors the financial impact of safety problems with its da Vinci Surgical System, including a number of deaths allegedly caused by the system.

A number of lawsuits have been filed against the company seeking damages for injuries caused by da Vinci. Following media coverage of those suits, ISRG's stock price suffered a significant decline. The filed investor lawsuit claims that ISRG deceived investors regarding the risk of Food and Drug Administration action against the company.

"We are concerned that ISRG failed to come clean with investors, especially in light of a significant number of deaths reported to the FDA," said Mr. Kathrein. "We are concerned that the company may be exposed to significant financial losses, either due to potential FDA restrictions on da Vinci or damages in pending personal injury lawsuits."

Investors who wish to serve as lead plaintiff in the case must move the court no later than June 25, 2013. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Hagens Berman reminds whistleblowers with inside information that rewards may be available to individuals who report information leading to a successful enforcement action by the Securities and Exchange Commission. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the law firm and its successes can be found at www.hbsslaw.com. The Firm's securities law blog is at http://www.meaningfuldisclosure.com.

Firmani + Associates
Mark Firmani, 206-443 9357
Mark@firmani.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INTUITIVE SURGICAL, INC.
08/19 INTUITIVE SURGICAL : Reports New Employee Option Grants for August 2016
08/17 Intuitive Surgical Reports New Employee Option Grants for August 2016
08/17 INTUITIVE SURGICAL : New Study Shows Robotic-Assisted Surgery Benefits For Ventr..
08/16 New Study Shows Robotic-Assisted Surgery Benefits For Ventral Hernia Patients
08/04 DEXTERA SURGICAL : DXTR) Enters Joint Development Program with Intuitive Surgica..
08/02 INTUITIVE SURGICAL : Hudson Valley Investment Advisors INC Decreased Stake in In..
07/21 INTUITIVE SURGICAL : Top Medical Companies Reach High Financial Strength
07/20 INTUITIVE SURGICAL : Appropriate Balance Financial Services Lowers stake in Intu..
07/20 INTUITIVE SURGICAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
07/20 MARKETS RIGHT NOW : US stocks end higher, led by technology
More news
Sector news : Advanced Medical Equipment & Technology - NEC
08/17DJAGILENT TECHNOLOGIES : Tech Tapers Annual Outlook Amid Slowing Life Sciences Sal..
08/15DJFisher & Paykel Files Patent Infringement Claim Against ResMed
08/02DJCERNER : Edges Annual Revenue Guidance Lower
07/29DJSony Reports Surprise Profit
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
More sector news : Advanced Medical Equipment & Technology - NEC
News from SeekingAlpha
08/21 13 Buys And 7 Sells From The Wide-Moat Universe
07/26 Einhorn a buyer of Chemours; American Capital Agency among sales
07/20 Intuitive Surgical Q2 2016 Conference Key Takeaways
07/20 Zimmer Biomet Becomes The Latest Ortho To Go Robotic
07/20 Intuitive Surgical (ISRG) Gary S. Guthart on Q2 2016 Results - Earnings Call ..
Advertisement
Financials ($)
Sales 2016 2 647 M
EBIT 2016 1 025 M
Net income 2016 663 M
Finance 2016 1 447 M
Yield 2016 -
P/E ratio 2016 39,13
P/E ratio 2017 33,94
EV / Sales 2016 9,45x
EV / Sales 2017 8,49x
Capitalization 26 465 M
More Financials
Chart INTUITIVE SURGICAL, INC.
Duration : Period :
Intuitive Surgical, Inc. Technical Analysis Chart | ISRG | US46120E6023 | 4-Traders
Full-screen chart
Technical analysis trends INTUITIVE SURGICA...
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 742 $
Spread / Average Target 7,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Gary S. Guthart President, Chief Executive Officer & Director
Lonnie M. Smith Chairman
Marshall L. Mohr Chief Financial Officer & Senior Vice President
Myriam J. Curet Chief Medical Officer & Senior Vice President
Alan J. Levy Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INTUITIVE SURGICAL, IN..25.88%26 465
THERMO FISHER SCIENTIF..7.97%60 385
BOSTON SCIENTIFIC CORP..31.29%32 944
PHILIPS10.29%27 681
ILLUMINA, INC.-11.96%24 774
EDWARDS LIFESCIENCES C..46.02%24 551
More Results